$FDC

FDC Limited is a Mumbai-based mid-size pharma company. You might know their brands — Electral (ORS sachets), Enerzal (energy drink), Zifi, Zocon : these are household names. They sell both in India and export internationally. Now the actual numbers (Consolidated, directly from the filing): Q4 FY26 Revenue: ₹584.8 Cr — up a solid 19% YoY from ₹491.9 Cr last Q4. Strong growth! Q4 FY26 PAT (Net Profit): ₹103.4 Cr — up a jaw-dropping 167% YoY from just ₹38.7 Cr in Q4 last year. That's nearly 3x profit in a single quarter! FY26 Full Year Revenue: ₹2,170 Cr — modest 3% growth over FY25's ₹2,108 Cr. FY26 Full Year PAT: ₹281 Cr — up ~5.5% from FY25's ₹267 Cr. Past Trend Check: Here's the real story : FY25 was actually a BAD year for FDC. Revenue grew 8.5% but PAT fell by 12.5% due to margin pressure. FY24 PAT was ₹305 Cr, FY25 dropped to ₹267 Cr. So FY26 PAT at ₹281 Cr is a recovery, but still below FY24 levels. The Q4 FY26 performance though is exceptional : especially that 167% profit jump which shows margins are back on track. Analyst Estimates vs Actual: Analysts expected Q4 revenue of ~₹520 Cr and PAT of ~₹58 Cr. FDC delivered ₹585 Cr revenue and ₹103 Cr PAT : comfortably beat on both counts by a wide margin. This is a genuine positive surprise. Competitors & Sector Context: Indian pharma sector had a mixed FY26. Cipla delivered strong results, while mid-size pharma peers saw pressure. FDC's 19% Q4 revenue growth stands out positively in this context. Company also received 1 USFDA approval in FY26, helping export prospects. Crux: Q4 alone is outstanding : 19% revenue growth and 167% profit jump. Full year is a recovery story after a weak FY25. Big analyst beat, improving margins, brand strength : this is a genuinely good result!